Is it safe to take sulfonamide antibiotics (e.g., sulfamethoxazole‑trimethoprim) during the first week after conception?

Safety of Sulfonamides in the First Week After Conception

Sulfonamide antibiotics, including sulfamethoxazole-trimethoprim (TMP-SMX), should be avoided during the first week after conception and throughout the first trimester unless no safer alternatives exist. The evidence consistently demonstrates potential teratogenic risks during early pregnancy, particularly for neural tube defects and oral clefts, though the absolute risk remains relatively low.

Evidence from Guidelines and FDA Labeling

The FDA classifies sulfamethoxazole-trimethoprim as Pregnancy Category C, indicating that animal studies have shown teratogenic effects and that the drug should only be used if potential benefits justify the risks 1. Specifically:

• Animal studies demonstrated cleft palates in rats at doses of 533 mg/kg sulfamethoxazole or 200 mg/kg trimethoprim
• In rabbits, doses 6 times the human therapeutic dose caused increased fetal loss and malformations
• The FDA label explicitly states: "sulfamethoxazole and trimethoprim should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus" 1

The 2020 ERS/TSANZ respiratory guidelines recommend avoiding co-trimoxazole during the first trimester (T1), noting that sulfonamide use is associated with potential fetal risks including hyperbilirubinemia and hemolytic anemia 2. They specifically state to "avoid during T1" and recommend 5 mg/day folic acid supplementation if use is necessary.

Birth Defect Associations

Multiple research studies have identified specific congenital anomalies associated with first-trimester sulfonamide exposure:

Neural tube defects and oral clefts are the most consistently reported associations. A 2014 systematic review found 31 infants with neural tube defects among women exposed to cotrimoxazole in the first trimester, yielding a crude prevalence of 0.7% 3. A 2016 case-control study among women with urinary tract infections found that trimethoprim-sulfamethoxazole use was associated with:

• Esophageal atresia (adjusted OR: 5.31,95% CI: 1.39-20.24)
• Diaphragmatic hernia (adjusted OR: 5.09,95% CI: 1.20-21.69) 4

However, context matters critically: The 2016 study controlled for confounding by indication by comparing different antibiotics among women with UTIs, strengthening the causal inference.

Spontaneous Abortion Risk

A 2018 nested case-control study of 77,429 pregnancies found that TMP-SMX exposure was associated with nearly tripled risk of spontaneous abortion (adjusted OR: 2.94,95% CI: 1.89-4.57) after controlling for confounders, indication bias, and protopathic bias 5. This represents one of the strongest pieces of evidence against early pregnancy use.

Clinical Decision-Making Algorithm

For the first week after conception (and throughout first trimester):

1. If treating a UTI or other bacterial infection:

   • First-line alternatives: Use nitrofurantoin (after first trimester), cephalexin, or amoxicillin instead
   • Reserve TMP-SMX only when culture sensitivities demonstrate resistance to all safer alternatives
   • The 2021 American College of Physicians guidelines recommend nitrofurantoin (5 days) or TMP-SMX (3 days) for uncomplicated cystitis, but this applies to non-pregnant women 6

2. If woman is already taking TMP-SMX when pregnancy discovered:

   • Discontinue immediately if clinically feasible
   • Switch to pregnancy-compatible alternative based on indication
   • Initiate folic acid supplementation (5 mg daily) if continuation is absolutely necessary

3. For HIV-positive women requiring prophylaxis:

   • The evidence is more nuanced here. A 2006 systematic review concluded that benefits of TMP-SMX prophylaxis in HIV-infected pregnant women likely outweigh risks in resource-limited settings 7
   • However, a 2025 trial in Zimbabwe found no benefit of TMP-SMX prophylaxis on birth weight 8, questioning routine prophylactic use

Important Caveats

Folic acid supplementation may ameliorate some teratogenic risk, as sulfonamides interfere with folate metabolism 1, 7. The 2025 EULAR guidelines note that sulfasalazine (a different sulfonamide used in rheumatology) can be continued during pregnancy with concomitant folic acid supplementation 9, but this applies to sulfasalazine specifically, not TMP-SMX.

Absolute risk remains relatively low: Even with the elevated odds ratios, the baseline risk of major birth defects is approximately 3-4%, and the absolute increase is measured in single percentage points. One retrospective study found no abnormalities in 10 children whose mothers received TMP-SMX during the first trimester 1, though this small sample size provides limited reassurance.

Confounding by indication is a persistent challenge in this literature—infections themselves may contribute to adverse outcomes. However, studies comparing different antibiotics for the same indication (like the 2016 UTI study 4) provide stronger evidence of drug-specific effects.

Bottom Line

The first week after conception represents a critical period of organogenesis where sulfonamide exposure should be avoided. While the absolute risk of birth defects remains relatively low (likely <5-7% vs. 3-4% baseline), the consistent signal across multiple studies for neural tube defects, oral clefts, and spontaneous abortion warrants using safer alternatives like beta-lactams or nitrofurantoin (after first trimester) whenever possible. The only exception would be life-threatening maternal infection with documented resistance to all safer alternatives, in which case TMP-SMX should be combined with high-dose folic acid supplementation.